Personalized Tumor Response Assessment in the Era of Molecular Medicine: Cancer-Specific and Therapy-Specific Response Criteria to Complement Pitfalls of RECIST

被引:135
|
作者
Nishino, Mizuki [1 ,2 ]
Jagannathan, Jyothi P. [1 ,2 ]
Krajewski, Katherine M. [1 ,2 ]
O'Regan, Kevin [1 ,2 ]
Hatabu, Hiroto [2 ]
Shapiro, Geoffrey [3 ]
Ramaiya, Nikhil H. [1 ,2 ]
机构
[1] Dana Farber Canc Inst, Dept Imaging, Boston, MA 02215 USA
[2] Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA
[3] Dana Farber Canc Inst, Early Drug Dev Ctr, Dept Med Oncol, Boston, MA 02215 USA
基金
美国国家卫生研究院;
关键词
CT; personalized medicine; RECIST; response assessment; GASTROINTESTINAL STROMAL TUMORS; RENAL-CELL CARCINOMA; GROWTH-FACTOR RECEPTOR; IMATINIB MESYLATE; LUNG-CANCER; METASTATIC MELANOMA; TARGETED THERAPY; TYROSINE KINASE; EFFICACY; GUIDELINES;
D O I
10.2214/AJR.11.7483
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
OBJECTIVE. The purpose of this article is to review cancer-and therapy-specific tumor response assessment criteria used in clinical trials and in practice, with illustrative case examples, and to discuss future directions toward "personalized" tumor response assessment. CONCLUSION. Although Response Evaluation Criteria in Solid Tumors will remain as the primary generalized criteria for response assessment, newer cancer-and therapy-specific criteria will play an important role in providing state-of-the-art response assessment of tumor following molecular targeted therapy and will contribute to personalized cancer care in the era of molecular medicine.
引用
收藏
页码:737 / 745
页数:9
相关论文
共 9 条
  • [1] New Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines for Advanced Non-Small Cell Lung Cancer: Comparison With Original RECIST and Impact on Assessment of Tumor Response to Targeted Therapy
    Nishino, Mizuki
    Jackman, David M.
    Hatabu, Hiroto
    Yeap, Beow Y.
    Cioffredi, Leigh-Anne
    Yap, Jeffrey T.
    Janne, Pasi A.
    Johnson, Bruce E.
    Van den Abbeele, Annick D.
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2010, 195 (03) : W221 - W228
  • [2] In silico cancer immunotherapy trials uncover the consequences of therapy-specific response patterns for clinical trial design and outcome
    Creemers, Jeroen H. A.
    Ankan, Ankur
    Roes, Kit C. B.
    Schroeder, Gijs
    Mehra, Niven
    Figdor, Carl G.
    de Vries, I. Jolanda M.
    Textor, Johannes
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [3] Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients
    Mayte Delgado-Ureña
    Francisco G. Ortega
    Diego de Miguel-Pérez
    Alba Rodriguez-Martínez
    Jose L. García-Puche
    Hugh Ilyine
    Jose A. Lorente
    Jose Exposito-Hernandez
    M. Carmen Garrido-Navas
    Miguel Delgado-Ramirez
    M. José Serrano
    Journal of Translational Medicine, 16
  • [4] Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients
    Delgado-Urena, Mayte
    Ortega, Francisco G.
    de Miguel-Perez, Diego
    Rodriguez-Martinez, Alba
    Garcia-Puche, Jose L.
    Ilyine, Hugh
    Lorente, Jose A.
    Exposito-Hernandez, Jose
    Carmen Garrido-Nayas, M.
    Delgado-Ramirez, Miguel
    Jose Serrano, M.
    JOURNAL OF TRANSLATIONAL MEDICINE, 2018, 16
  • [5] Intra- and inter-reader agreement of iRECIST and RECIST 1.1 criteria for the assessment of tumor response in patients receiving checkpoint inhibitor immunotherapy for lung cancer
    Castellanos, Sandra Huicochea
    Pagano, Andrew
    Plodkowski, Andrew J.
    Girshman, Jeffrey
    Hellmann, Matthew D.
    Rizvi, Hira
    Flynn, Jessica
    Zheng, Junting
    Capanu, Marinela
    Halpenny, Darragh F.
    Ginsberg, Michelle S.
    LUNG CANCER, 2021, 161 : 60 - 67
  • [6] Prostate-specific Membrane Antigen PET: Therapy Response Assessment in Metastatic Prostate Cancer
    Barbosa, Felipe G.
    Queiroz, Marcelo A.
    Ferraro, Daniela A.
    Nunes, Rafael F.
    Dreyer, Priscilla R.
    Zaniboni, Elaine C.
    Costa, Larissa B.
    Bastos, Diogo A.
    Marin, Jose Flavio G.
    Buchpiguel, Carlos A.
    RADIOGRAPHICS, 2020, 40 (05) : 1412 - 1430
  • [7] MHC class I-presented lung cancer-associated tumor antigens identified by immunoproteomics analysis are targets for cancer-specific T cell response
    Shetty, Vivekananda
    Sinnathamby, Gomathinayagam
    Nickens, Zacharie
    Shah, Punit
    Hafner, Julie
    Mariello, Lisa
    Kamal, Shivali
    Vlahovic', Gordana
    Lyerly, H. Kim
    Morse, Michael A.
    Philip, Ramila
    JOURNAL OF PROTEOMICS, 2011, 74 (05) : 728 - 743
  • [8] Chinese herbal medicine combined with oxaliplatin-based chemotherapy for advanced gastric cancer: A systematic review and meta-analysis of contributions of specific medicinal materials to tumor response
    Tan, Ying
    Wang, Heping
    Xu, Bowen
    Zhang, Xiaoxiao
    Zhu, Guanghui
    Ge, Yuansha
    Lu, Taicheng
    Gao, Ruike
    Li, Jie
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [9] Differential organ-specific tumor response to first-line immune checkpoint inhibitor therapy in non-small cell lung cancer- a retrospective cohort study
    Wang, Qi
    Fang, Yujia
    Li, Chunyu
    Leong, Tracy L.
    Provencio, Mariano
    Oh, In-Jae
    Zhang, Zhemin
    Su, Chunxia
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (02) : 312 - 321